NuCana plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly21.5MTarget: Sufficient to fund operations into 2029
Phase 2 NuTide:701 Patient Enrollment QuarterlyTarget: Complete enrollment in the first half of 2026
Quarterly Net Loss Quarterly-3.9MTarget: Minimize cash burn through disciplined R&D spending
Watch Items
- NUC-7738 Phase 2 NuTide:701 Final Data ReadoutTrigger: Release of final clinical data in PD-1 inhibitor-resistant metastatic melanomaAction: Evaluate efficacy (objective response rate, disease control rate) and safety profile to support registrational strategy
- FDA Regulatory Guidance for NUC-7738Trigger: Obtaining official feedback from the FDA regarding a registrational pathway in melanomaAction: Refine clinical development plan and prepare protocol for potential registrational trials
- NUC-3373 Combination Strategy CharacterizationTrigger: Completion of evaluation of optimal combinations and target indicationsAction: Formulate and announce plans for future clinical studies of NUC-3373
Research as of 20 Jun 2026